From: manufacturing CHEMIST
Published on September 16, 2024
Abstract: In the rapidly evolving pharmaceutical landscape, targeted protein degraders (TPDs) represent a significant leap forward. TPDs offer a novel therapeutic modality with the potential to address disease-causing proteins that have traditionally been difficult to target with conventional small molecules.
During the past two decades, since the concept of utilising the ubiquitin-proteasome system to degrade target proteins was introduced, targeted protein degradation has transitioned beyond academic research to industrial application.
Numerous companies are now advancing preclinical and early clinical development programmes, illustrating the growing interest and potential of this approach, explains Jinling Chen, Ph.D., Senior Vice President, Head of Pharmaceutical Development and Manufacturing at WuXi STA (a subsidiary of WuXi AppTec).
